Mounjaro vs Zepbound, FDA labels revised August 2026 (read November 8, 2026); prices with read dates as shown
MounjaroZepbound
MoleculeTirzepatideTirzepatide
Approved forType 2 diabetes (adults, ages 10+); CV risk reduction in high-risk adults with type 2 diabetesWeight management in adults; moderate-to-severe sleep apnea in adults with obesity
First approvedMay 13, 2022November 8, 2023
Strengths2.5, 5, 7.5, 10, 12.5, 15 mg2.5, 5, 7.5, 10, 12.5, 15 mg
Maintenance per labelDose raised as needed for glucose control; max 15 mg (10 mg in children)5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea
FormsSingle-dose pen, single-dose vial, multi-dose vial, KwikPenSingle-dose pen, single-dose vial, multi-dose vial, KwikPen
Self-pay price we foundMochi Health "as low as" $499 at 2.5 mg (provider page, read Oct 15, 2026)Lilly KwikPen $299 to $449 by dose, with refill rules (read Oct 15, 2026)
Medicare GLP-1 BridgeNot covered (people with type 2 diabetes are excluded)KwikPen only, $50 copay if eligible

Are Mounjaro and Zepbound the same medicine?

They contain the same molecule, tirzepatide, made by the same company, in the same strengths and presentations. What differs is the FDA approval each brand carries.

FDA approves a drug for specific uses based on the trials submitted. Lilly's SURPASS trials in type 2 diabetes supported Mounjaro. Its SURMOUNT trials in obesity, and two sleep apnea trials, supported Zepbound. Each brand's label, dose guidance and patient information are written for its own uses. In practice the doses look alike, but the maintenance guidance differs: Zepbound names 5, 10 or 15 mg for weight, while Mounjaro's dose is adjusted for blood sugar.

Who is each one for?

Mounjaro is for people with type 2 diabetes. Zepbound is for people with obesity, or overweight plus a weight-related condition, and for adults with obesity and moderate-to-severe obstructive sleep apnea.

If you have type 2 diabetes and obesity, both could be clinically reasonable; which brand your prescriber writes usually comes down to your diagnosis codes and what your plan will pay for. Read more on the Mounjaro and Zepbound pages.

Why does insurance treat them differently?

Many plans cover diabetes drugs but exclude drugs for weight management. Because the label decides which category a brand falls into, Mounjaro is often covered for type 2 diabetes while Zepbound runs into weight-drug exclusions.

Walmart's 2027 benefits are an example of that split. CNBC reported on October 13, 2026 that Walmart will offer Mounjaro and Ozempic at no cost to employees with type 2 diabetes after a new prior authorization, while still not covering GLP-1s for weight loss. That is a news report; we did not read Walmart's plan documents.

Medicare runs the other way for weight. The Medicare GLP-1 Bridge covers the Zepbound KwikPen, Wegovy and Foundayo at a $50 monthly copay from July 1, 2026 through December 31, 2027, but people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible. Medicare.gov says their Part D plan "might cover" a GLP-1; for people with diabetes, that is typically where Mounjaro sits. Our insurance coverage guide and Part D page go deeper.

What do they cost without insurance?

Zepbound has a published manufacturer self-pay program; for Mounjaro we found only provider prices.

Self-pay prices we found; Lilly terms read October 15, 2026 (1 month = 28 days; savings end December 31, 2026); provider pages read on the dates shown
ProductPriceBasis
Zepbound KwikPen 2.5 mg$299Lilly self-pay
Zepbound KwikPen 5 mg$399Lilly self-pay
Zepbound KwikPen 7.5 to 15 mg$449 with each refill within 45 days; otherwise $499 (7.5 mg) or $699 (10 to 15 mg)Lilly self-pay, 11 fills a calendar year
Mounjaro 2.5 mg"As low as" $499, membership extraMochi Health page, read Oct 15, 2026
Mounjaro and Zepbound pens$1,899 a month, membership extraHims & Hers page, read Sept 17, 2026

As arithmetic only, at the 2.5 mg starting dose a month of Zepbound KwikPen through Lilly ($299) costs $200 less than Mochi's lowest printed Mounjaro price ($499), before Mochi's separately billed membership, which its pages showed as $199 for 12 months or $17 a month on October 15, 2026. We could not read Lilly's Mounjaro list price; its pricing page returned an error on November 8, 2026.

What about compounded tirzepatide?

Compounded tirzepatide is neither Mounjaro nor Zepbound. It is made with the drug in those brands, but it is not the same product and is not FDA-approved. Across 24 compounded programs in our price table, the median lowest all-in monthly price was $149, on reads dated October 15, 2026 (NexLife November 6, 2026). The tirzepatide guide covers its regulatory status, including FDA's September 2026 warning letter to Empower Pharmacy.

Do they share the same warnings?

Yes. Both labels carry the boxed warning for thyroid C-cell tumors seen in rats and the contraindication for people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both warn about pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach and bowel effects, allergic reactions and aspiration under anesthesia, and both say a KwikPen must never be shared.

Frequently asked questions

Is Zepbound just Mounjaro for weight loss?

In molecule terms, yes: both are tirzepatide in the same strengths. But they are separate FDA approvals with separate labels. Zepbound is approved for weight management and sleep apnea in adults; Mounjaro for type 2 diabetes in adults and children 10 and older, plus heart risk reduction in high-risk adults with type 2 diabetes. Coverage and pricing follow those labels.

Which is cheaper without insurance, Mounjaro or Zepbound?

On the prices we found, Zepbound through Lilly's self-pay program was $299 to $449 a month by dose (read October 15, 2026), while Mochi Health's lowest printed Mounjaro price was $499 at 2.5 mg, plus membership. We could not read Lilly's Mounjaro list price. These are dated reads, not current quotes.

Can I get Mounjaro if I don't have diabetes?

Mounjaro's label covers type 2 diabetes. A prescriber can choose to use a drug outside its label, but insurers usually require a type 2 diabetes diagnosis to pay for Mounjaro. For weight management without diabetes, the same molecule is approved as Zepbound, which has its own self-pay program and is covered by the Medicare GLP-1 Bridge as a KwikPen.

Does Medicare cover Mounjaro or Zepbound?

The Medicare GLP-1 Bridge covers the Zepbound KwikPen for eligible enrollees at a $50 monthly copay through December 31, 2027; vials and single-dose pens are excluded. People with type 2 diabetes are not eligible for the Bridge, but Medicare.gov says their Part D plan might cover a GLP-1, which is where Mounjaro coverage would usually come from.

Do Mounjaro and Zepbound have the same side effects?

Both labels list stomach and bowel effects such as nausea, diarrhea, vomiting and constipation as the most common, and share the same boxed warning for thyroid C-cell tumors in rats. In Zepbound's weight trials, nausea affected 25% to 29% versus 8% on placebo. Mounjaro adds warnings about low blood sugar with insulin or sulfonylureas, relevant in diabetes.

Sources

  1. FDA label (DailyMed): Mounjaro prescribing information — label revised August 2026; read 2026-11-08
  2. FDA label (DailyMed): Zepbound prescribing information — label revised 08/2026; read 2026-11-08
  3. Medicare.gov: Weight loss drugs (Medicare GLP-1 Bridge) — read 2026-11-08
  4. Lilly: LillyDirect Zepbound self-pay terms — read 2026-10-15; re-read blocked 2026-11-08
  5. CNBC: Walmart employee benefits add no-cost GLP-1s in 2027 — news report published October 13, 2026; read 2026-11-08
  6. Mochi Health: per-dose pricing — read 2026-10-15
  7. Hims & Hers: weight loss pricing — read 2026-09-17

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.